KR102889562B1 - 아자-퀴놀린 화합물 및 그의 용도 - Google Patents
아자-퀴놀린 화합물 및 그의 용도Info
- Publication number
- KR102889562B1 KR102889562B1 KR1020227011716A KR20227011716A KR102889562B1 KR 102889562 B1 KR102889562 B1 KR 102889562B1 KR 1020227011716 A KR1020227011716 A KR 1020227011716A KR 20227011716 A KR20227011716 A KR 20227011716A KR 102889562 B1 KR102889562 B1 KR 102889562B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- methyl
- cyclohexyl
- trans
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019108296 | 2019-09-26 | ||
| CNPCT/CN2019/108296 | 2019-09-26 | ||
| PCT/CN2020/117487 WO2021057853A1 (en) | 2019-09-26 | 2020-09-24 | Aza-quinoline compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220070229A KR20220070229A (ko) | 2022-05-30 |
| KR102889562B1 true KR102889562B1 (ko) | 2025-11-24 |
Family
ID=75166744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227011716A Active KR102889562B1 (ko) | 2019-09-26 | 2020-09-24 | 아자-퀴놀린 화합물 및 그의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12544374B2 (https=) |
| EP (1) | EP4034535B1 (https=) |
| JP (1) | JP7763753B2 (https=) |
| KR (1) | KR102889562B1 (https=) |
| CN (1) | CN114746414B (https=) |
| AU (1) | AU2020355837B2 (https=) |
| CA (1) | CA3150284A1 (https=) |
| DK (1) | DK4034535T3 (https=) |
| IL (1) | IL291499B2 (https=) |
| WO (1) | WO2021057853A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7763753B2 (ja) | 2019-09-26 | 2025-11-04 | ノバルティス アーゲー | アザキノリン化合物およびその使用 |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| AU2022412837A1 (en) * | 2021-12-16 | 2024-06-13 | Teijin Pharma Limited | Cdk9 inhibitor and use thereof |
| CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
| CN118515653B (zh) * | 2024-07-23 | 2024-12-10 | 西湖制药(杭州)有限公司 | 一种ezh2特异性抑制剂及其制备方法和用途 |
| CN118598873B (zh) * | 2024-08-07 | 2024-11-19 | 艾斯拓康生物医药(天津)有限公司 | 一种手性的氮杂-喹啉类化合物的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016103155A1 (en) | 2014-12-23 | 2016-06-30 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
| WO2017002064A1 (en) | 2015-06-30 | 2017-01-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
| CN1653059A (zh) | 2002-03-08 | 2005-08-10 | 卫材株式会社 | 用作医药品的大环化合物 |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2014155301A1 (en) | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
| KR20190084063A (ko) | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 |
| JP7763753B2 (ja) | 2019-09-26 | 2025-11-04 | ノバルティス アーゲー | アザキノリン化合物およびその使用 |
-
2020
- 2020-09-24 JP JP2022519331A patent/JP7763753B2/ja active Active
- 2020-09-24 CA CA3150284A patent/CA3150284A1/en active Pending
- 2020-09-24 KR KR1020227011716A patent/KR102889562B1/ko active Active
- 2020-09-24 DK DK20868772.3T patent/DK4034535T3/da active
- 2020-09-24 US US17/632,990 patent/US12544374B2/en active Active
- 2020-09-24 AU AU2020355837A patent/AU2020355837B2/en active Active
- 2020-09-24 EP EP20868772.3A patent/EP4034535B1/en active Active
- 2020-09-24 WO PCT/CN2020/117487 patent/WO2021057853A1/en not_active Ceased
- 2020-09-24 CN CN202080067448.9A patent/CN114746414B/zh active Active
- 2020-09-24 IL IL291499A patent/IL291499B2/en unknown
-
2025
- 2025-11-21 US US19/396,743 patent/US20260076968A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016103155A1 (en) | 2014-12-23 | 2016-06-30 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
| WO2017002064A1 (en) | 2015-06-30 | 2017-01-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| IL291499A (en) | 2022-05-01 |
| KR20220070229A (ko) | 2022-05-30 |
| CA3150284A1 (en) | 2021-04-01 |
| AU2020355837B2 (en) | 2025-10-02 |
| EP4034535A1 (en) | 2022-08-03 |
| JP2022550353A (ja) | 2022-12-01 |
| IL291499B2 (en) | 2025-08-01 |
| CN114746414A (zh) | 2022-07-12 |
| JP7763753B2 (ja) | 2025-11-04 |
| US20220280509A1 (en) | 2022-09-08 |
| IL291499B1 (en) | 2025-04-01 |
| US12544374B2 (en) | 2026-02-10 |
| WO2021057853A1 (en) | 2021-04-01 |
| CN114746414B (zh) | 2024-10-18 |
| EP4034535A4 (en) | 2023-11-22 |
| AU2020355837A1 (en) | 2022-02-24 |
| EP4034535B1 (en) | 2026-03-04 |
| DK4034535T3 (da) | 2026-04-07 |
| US20260076968A1 (en) | 2026-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102889562B1 (ko) | 아자-퀴놀린 화합물 및 그의 용도 | |
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| EP3472161B1 (en) | Triazolopyridine compounds and uses thereof | |
| US10604502B2 (en) | Substituted 5-cyanoindole compounds and uses thereof | |
| JP2019524872A (ja) | 癌の治療に有用なイミダゾピリミジン化合物 | |
| EP4041725B1 (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| HK40077297B (zh) | 氮杂-喹啉化合物及其用途 | |
| HK40077297A (en) | Aza-quinoline compounds and uses thereof | |
| HK40080941B (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| HK40080941A (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |